BENznidazole Evaluation For Interrupting Trypanosomiasis Trial
| < back
The purpose of this study is to determine if 60 days of treatment with an antiparasitic drug (benznidazole) could prevent the progression of cardiac disease in patients with Chagas disease. The BENEFIT study is being conducted by the Population Health Research Institute (in Hamilton, Canada) and the Institute Dante Pazzanese de Cardiologia (Sao Paulo, Brazil) together with an independent Steering Committee.
Study Design: Double-Blind, Placebo Control, Randomized, Safety/Efficacy Study, Single Group Assignment, Treatment.
Length of Study: 5 years
# of Patients: 3,000
Patient Populations: Chagas' disease, Chagas' infection, any combination of 2 positive tests.
Available upon study completion.
Publications (for a full listing of publications, please visit the 'Media and Publications' section)
Marin-Neto, JA, Raasi Jr., A, Morillo, CA, Avezum, A, Connolly, SJ, Sosa-Estani, S, Rosas, F, Yusuf, S for the BENEFIT Investigators. Rational and design of a randomized placebo-controlled assessing the effects of etiologic treatment in Chagas' cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosmiasis (BENEFIT). AM Heart J; 2008; 156(1): 37-43.